每天两次或每天一次的0.01%的阿特罗宾用于儿童近视控制:一个随机对照试验
Meinan He1, Ziyu Zhang1, Louis Tong2
1Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Eye (London, England)
|October 1, 2025
概括
与每晚一次剂量相比,每天两次0.01%的阿特罗平眼滴显著减少了儿童近视的进展. 这种增强的疗法减缓了轴延长和折射误差的变化,没有任何不良影响.
科学领域:
- 眼科医生 眼科 眼科
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 近视的进展是儿童日益关注的问题.
- 标准的0.01%的氨酸用于减缓近视.
- 对于0.01%的阿特罗宾,最优的剂量频率需要进行研究.
研究的目的:
- 为了比较0.01%的阿特罗宾眼滴每天服用两次的疗效与每晚服用一次的疗效,用于控制近视.
- 评估不同0.01%的阿特罗宾剂量频率的安全性.
主要方法:
- 一个为期一年的随机对照试验,涉及70名6至13岁的近视儿童.
- 参与者每晚一次 (QD) 或每天两次 (BID) 接受0.01%的氨酸眼滴.
- 主要终点是轴长度 (AL) 的变化;球体等效 (SE) 的进展也被监测.
主要成果:
- 每天两次 (BID) 组显示与每晚一次 (QD) 组 (0.32 mm) 相比,轴延长 (0.21 mm) 显著减少,减少了34%.
- 两用治疗方案在减缓SE进展方面比BID疗法更有效53% (-0.66D对比-0.31D).
- 安全参数和视觉功能仍然相似,在BID组中,只有中视瞳孔直径的临床上可接受的增加.
结论:
- 每天两次0.01%的阿特罗平比每晚一次的剂量更有效地控制了儿童近视的进展.
- 增强的疗效在没有显著增加不良影响的情况下实现.
- 这一发现支持优化阿特罗剂量频率,以改善近视管理.
相关概念视频
01:11Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
01:27Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
01:28Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K